NCT00584740View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Crohn's Disease
Interventions
DRUG

AIN457

10 mg/kg

DRUG

Placebo

Matching placebo to AIN457

Trial Locations (2)

10117

Novartis Investigative Site, Berlin

70376

Novartis Investigative Site, Stuttgart

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY